Cargando…

Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation with an annual incidence rate of 3–5% in lung-transplant recipients. Pathogenesis indicates a strong association with functional over-immunosuppression and EBV infection. Clinical impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afshar, Kamyar, Rao, A. Purush, Patel, Vipul, Forrester, Kevin, Ganesh, Sivagini
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056220/ https://www.ncbi.nlm.nih.gov/pubmed/21423547 http://dx.doi.org/10.1155/2011/919651

Ejemplares similares

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)

Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus
por: Menghi, Viola, et al.
Publicado: (2016)

Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection
por: Vial, Romain, et al.
Publicado: (2017)

Foscarnet-Resistant Cytomegalovirus Esophagitis with Stricturing
por: Gaduputi, Vinaya, et al.
Publicado: (2013)

The Successful Treatment of a Cord Blood Transplant Recipient with Varicella Zoster Virus Meningitis, Radiculitis and Myelitis with Foscarnet
por: Shimizu, Ryo, et al.
Publicado: (2017)

CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins
por: Vassallo, Francesco, et al.
Publicado: (2020)

Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants
por: Metafuni, Elisabetta, et al.
Publicado: (2018)

Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD
por: Habib, Mohammed, et al.
Publicado: (2017)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

Late Onset Graft Plasmacytoma-Like PTLD Presenting as Acute Hyperglycemia in a Kidney-Pancreas Transplant Recipient
por: Ventura-Aguiar, P., et al.
Publicado: (2019)

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
por: Choquet, Sylvain, et al.
Publicado: (2023)

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Sanz-Caballer, J., et al.
Publicado: (2022)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
por: Lau, Eric, et al.
Publicado: (2021)

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
por: Compagno, Francesca, et al.
Publicado: (2020)

Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration
por: Yu, Yedong, et al.
Publicado: (2021)

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Dharnidharka, V., et al.
Publicado: (2022)

Relapsing EBV encephalitis in a renal transplant recipient
por: Stone, Joshua A., et al.
Publicado: (2017)

Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy
por: Hakki, Morgan
Publicado: (2020)

P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES
por: Choquet, S., et al.
Publicado: (2022)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

Foscarnet-induced genital lesions: An overview with a case report
por: Adalsteinsson, Jonas A., et al.
Publicado: (2018)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients
por: Liu, Yan, et al.
Publicado: (2023)

Abstract 3 Efficacy of Foscarnet in Preventing HHV6 Encephalitis in Adult Single Cord Blood Transplantation
por: Suzuki, Kotaro, et al.
Publicado: (2023)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study
por: Chaganti, Sridhar, et al.
Publicado: (2023)

A CASE OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A POST-DOUBLE LUNG TRANSPLANT PATIENT WITH COVID-19
por: KO, JUSTINE, et al.
Publicado: (2021)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

Phosphonoformate Crystalluria, A Warning Signal of Foscarnet-Induced Kidney Injury
por: Deffert, Christine, et al.
Publicado: (2020)

Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy
por: Khorenko, Mikhail, et al.
Publicado: (2022)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

Human Herpesvirus-6 Pneumonitis around the Engraftment of Cord Blood Transplantation following Foscarnet Prophylaxis in a Patient with Acute Leukemia
por: Ishio, Takashi, et al.
Publicado: (2015)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients
por: Engels, Eric A., et al.
Publicado: (2018)

Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation
por: Rausch, Lisa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iftjdnq4ll9uks5mgtovgeq9sk